Is Uniqure NV (QURE) overvalued? · rev $16.1M
Uniqure NV (QURE) is a biotechnology company listed on NASDAQ.
This page asks whether Uniqure NV (QURE) looks expensive on cached numbers — not a short thesis.
Latest reported QURE revenue for 2025-12-31 was $16.1M. Net income was -$199.0M. Revenue was down 40.6% from 2024-12-31 to 2025-12-31. QURE currently screens at market cap $3.04B.
QURE currently screens at market cap $3.04B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next QURE 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the QURE stock page for the full model, not this heading.
Not investment advice.